Navigation Links
ChromaDex® Names Debra Heim as COO

IRVINE, Calif., Feb. 21, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries and marketer of BluScience™ (, its recently launched line of dietary supplements, announced today the Board has appointed Debra A. Heim as the company's Chief Operating Officer and President of its Consumer Products Division.


Debra Heim, age 43, has over 20 years of experience with consumer brands companies. Prior to joining ChromaDex, Ms. Heim spent 16 years with The Himmel Group ( where she served as its President and Chief Operating Officer since 2010. Previously, she served as the company's Chief Financial Officer for 12 years. During her tenure with The Himmel Group, Ms. Heim was part of the executive management team overseeing sales and marketing of the GOLD BOND MEDICATED POWDER and OVALTINE® businesses. Additionally, Debra built and managed the organization responsible for the manufacturing, sales order processing, distribution, accounting and finance, information technology systems, human resources and consumer services of the company.

Commenting on the announcement, ChromaDex's CEO Jeffrey Himmel stated, "Having personally worked with Debra for more than 15 years, I am thrilled to have her join the executive management team at ChromaDex. Her experience and skill sets with branded consumer products are an ideal fit, as we are just beginning the national retail launch of our BluScience line of dietary supplements."

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® ( pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:                                             
Liviakis Financial Communications, Inc.                         
John M. Liviakis, President                                                       

Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President

ChromaDex/BluScience Contact:
Jeffrey Himmel, CEO

SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson
2. ChromaDex® Announces Management Changes
3. Entomological Society of America names 2008 award winners
4. American Library Association names NJIT prof’s Whale Music book a top ten
5. WCC Smart Search and Match Names Rudie Lion - Product Marketing Manager
6. WCC Smart Search and Match Names Rudie Lion - Product Marketing Manager
7. WCC Smart Search & Match Names Tarvinder Sembhi as VP Sales for the ID Market
8. Names turn preschoolers into vegetable lovers
9. AIBS names 2009 emerging public policy leaders
10. UC Riverside researcher names lichen after President Barack Obama
11. Impact Factor names Cell top research journal
Post Your Comments:
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology: